CDC Panel Recommends Ending Universal Hepatitis B Vaccination at Birth
The CDC's Advisory Committee on Immunization Practices voted to discontinue the universal recommendation for hepatitis B vaccination at birth, advising vaccination only for infants of mothers who test positive for the virus.
The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted 8-3 to end the longstanding recommendation that all newborns receive the hepatitis B vaccine at birth. The new guidance advises that only infants born to mothers who test positive for hepatitis B should receive the vaccine at birth, while others should consult with healthcare providers to determine the appropriate timing for vaccination.
This decision has drawn criticism from public health experts who highlight the previous policy's success in significantly reducing hepatitis B cases among children since its implementation in 1991. Dr. Grant Paulsen, representing the Pediatric Infectious Diseases Society, questioned the rationale behind changing a policy that has been effective, citing concerns that may be more theoretical than real.
The ACIP's recommendation is not yet official and requires approval from the CDC's acting director. If enacted, this would mark a significant shift in U.S. vaccination policy, potentially affecting the incidence of hepatitis B among children.